Comparative Pharmacology
Head-to-head clinical analysis: ORSYTHIA versus ORTHO NOVUM 1 80 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORSYTHIA versus ORTHO NOVUM 1 80 28.
ORSYTHIA vs ORTHO-NOVUM 1/80 28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal aromatase inhibitor that selectively and reversibly inhibits aromatase, the enzyme responsible for converting androgens to estrogens, thereby reducing estrogen levels in tissues.
Combination estrogen-progestin contraceptive; primarily inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
400 mg orally twice daily
One tablet orally once daily at the same time each day for 28 days (21 active tablets containing norethindrone 1 mg and ethinyl estradiol 80 mcg, followed by 7 placebo tablets).
None Documented
None Documented
Terminal half-life ~12 hours (range 10-14 h); prolonged in renal impairment (up to 24-30 h).
Norethindrone: 7-8 hours; mestranol: 10-13 hours (terminal). Steady-state achieved in 5-7 days.
Primarily renal (≥90% as unchanged drug); <5% biliary/fecal.
Norethindrone: 50-60% renal, 20-30% fecal; mestranol: 30-40% renal, 60-70% fecal.
Category C
Category C
Hormonal Contraceptive
Hormonal Contraceptive